![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
AL amyloidosis is the most common form of systemic amyloidosis and is associated with an underlying plasma cell dyscrasia. This review outlines an overview of high-dose intravenous melphalan and stem cell transplantation in the treatment of AL amyloidosis. An algorithm of our recommendations for the treatment of AL amyloidosis is also outlined.
| Abbreviations | ||
| HDM/SCT | = | high-dose melphalan and stem cell transplantation |
| CR | = | hematologic complete response |
| FLC | = | serum free light chain concentration |
| TRM | = | treatment-related mortality |
| Abbreviations | ||
| HDM/SCT | = | high-dose melphalan and stem cell transplantation |
| CR | = | hematologic complete response |
| FLC | = | serum free light chain concentration |
| TRM | = | treatment-related mortality |